DRUG DEVELOP RES 润色咨询

DRUG DEVELOPMENT RESEARCH

出版年份：1981 年文章数：827 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：3.4% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1182175, encodeId=f5d711821e569, content=这杂志没有中国人投吗？？咋没见几个评论呢。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Jan 08 12:31:41 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112395, encodeId=874c211239578, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：2022.1投递，2022.5接收，审稿人和编辑很认真，来回修改了3次，提出意见也很好，对细节也很在意。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ce75164092, createdName=146c1fd7m83暂无昵称, createdTime=Tue Jan 31 15:26:26 CST 2023, time=2023-01-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102645, encodeId=6b942102645fe, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：小分子药物<br>经验分享：很快，一审1个月，两个审稿人都很nice,按要求补了实验一个月修回，然后半个月就接收了！很好的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5862524433, createdName=NGDZTPBCG, createdTime=Fri Nov 25 20:21:09 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1089798, encodeId=0c3d1089e98bd, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089797, encodeId=25af1089e97d6, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=542103, encodeId=a9be542103d1, content=从1.5分以下,现在接近2分,是好现象,这个杂志是你值得拥有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiqi, createdTime=Fri Jul 14 18:48:00 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2022-01-08 第五先生

    这杂志没有中国人投吗？？咋没见几个评论呢。。

    4

    展开4条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1182175, encodeId=f5d711821e569, content=这杂志没有中国人投吗？？咋没见几个评论呢。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Jan 08 12:31:41 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112395, encodeId=874c211239578, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：2022.1投递，2022.5接收，审稿人和编辑很认真，来回修改了3次，提出意见也很好，对细节也很在意。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ce75164092, createdName=146c1fd7m83暂无昵称, createdTime=Tue Jan 31 15:26:26 CST 2023, time=2023-01-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102645, encodeId=6b942102645fe, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：小分子药物<br>经验分享：很快，一审1个月，两个审稿人都很nice,按要求补了实验一个月修回，然后半个月就接收了！很好的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5862524433, createdName=NGDZTPBCG, createdTime=Fri Nov 25 20:21:09 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1089798, encodeId=0c3d1089e98bd, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089797, encodeId=25af1089e97d6, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=542103, encodeId=a9be542103d1, content=从1.5分以下,现在接近2分,是好现象,这个杂志是你值得拥有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiqi, createdTime=Fri Jul 14 18:48:00 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2023-01-31 146c1fd7m83暂无昵称 来自浙江省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：药理
    经验分享：2022.1投递，2022.5接收，审稿人和编辑很认真，来回修改了3次，提出意见也很好，对细节也很在意。

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1182175, encodeId=f5d711821e569, content=这杂志没有中国人投吗？？咋没见几个评论呢。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Jan 08 12:31:41 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112395, encodeId=874c211239578, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：2022.1投递，2022.5接收，审稿人和编辑很认真，来回修改了3次，提出意见也很好，对细节也很在意。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ce75164092, createdName=146c1fd7m83暂无昵称, createdTime=Tue Jan 31 15:26:26 CST 2023, time=2023-01-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102645, encodeId=6b942102645fe, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：小分子药物<br>经验分享：很快，一审1个月，两个审稿人都很nice,按要求补了实验一个月修回，然后半个月就接收了！很好的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5862524433, createdName=NGDZTPBCG, createdTime=Fri Nov 25 20:21:09 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1089798, encodeId=0c3d1089e98bd, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089797, encodeId=25af1089e97d6, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=542103, encodeId=a9be542103d1, content=从1.5分以下,现在接近2分,是好现象,这个杂志是你值得拥有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiqi, createdTime=Fri Jul 14 18:48:00 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2022-11-25 NGDZTPBCG 来自上海

    审稿速度:1.0 | 投稿命中率:75.0
    偏重的研究方向：小分子药物
    经验分享：很快，一审1个月，两个审稿人都很nice,按要求补了实验一个月修回，然后半个月就接收了！很好的杂志

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1182175, encodeId=f5d711821e569, content=这杂志没有中国人投吗？？咋没见几个评论呢。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Jan 08 12:31:41 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112395, encodeId=874c211239578, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：2022.1投递，2022.5接收，审稿人和编辑很认真，来回修改了3次，提出意见也很好，对细节也很在意。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ce75164092, createdName=146c1fd7m83暂无昵称, createdTime=Tue Jan 31 15:26:26 CST 2023, time=2023-01-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102645, encodeId=6b942102645fe, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：小分子药物<br>经验分享：很快，一审1个月，两个审稿人都很nice,按要求补了实验一个月修回，然后半个月就接收了！很好的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5862524433, createdName=NGDZTPBCG, createdTime=Fri Nov 25 20:21:09 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1089798, encodeId=0c3d1089e98bd, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089797, encodeId=25af1089e97d6, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=542103, encodeId=a9be542103d1, content=从1.5分以下,现在接近2分,是好现象,这个杂志是你值得拥有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiqi, createdTime=Fri Jul 14 18:48:00 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2021-12-29 桑晒麦拉

    什么是Protocol？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1182175, encodeId=f5d711821e569, content=这杂志没有中国人投吗？？咋没见几个评论呢。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Jan 08 12:31:41 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112395, encodeId=874c211239578, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：2022.1投递，2022.5接收，审稿人和编辑很认真，来回修改了3次，提出意见也很好，对细节也很在意。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ce75164092, createdName=146c1fd7m83暂无昵称, createdTime=Tue Jan 31 15:26:26 CST 2023, time=2023-01-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102645, encodeId=6b942102645fe, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：小分子药物<br>经验分享：很快，一审1个月，两个审稿人都很nice,按要求补了实验一个月修回，然后半个月就接收了！很好的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5862524433, createdName=NGDZTPBCG, createdTime=Fri Nov 25 20:21:09 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1089798, encodeId=0c3d1089e98bd, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089797, encodeId=25af1089e97d6, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=542103, encodeId=a9be542103d1, content=从1.5分以下,现在接近2分,是好现象,这个杂志是你值得拥有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiqi, createdTime=Fri Jul 14 18:48:00 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2021-12-27 msSSSSSD

    什么是comment？

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1182175, encodeId=f5d711821e569, content=这杂志没有中国人投吗？？咋没见几个评论呢。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=45, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6c25584198, createdName=第五先生, createdTime=Sat Jan 08 12:31:41 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112395, encodeId=874c211239578, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：2022.1投递，2022.5接收，审稿人和编辑很认真，来回修改了3次，提出意见也很好，对细节也很在意。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ce75164092, createdName=146c1fd7m83暂无昵称, createdTime=Tue Jan 31 15:26:26 CST 2023, time=2023-01-31, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102645, encodeId=6b942102645fe, content=审稿速度:1.0 | 投稿命中率:75.0<br>偏重的研究方向：小分子药物<br>经验分享：很快，一审1个月，两个审稿人都很nice,按要求补了实验一个月修回，然后半个月就接收了！很好的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e5862524433, createdName=NGDZTPBCG, createdTime=Fri Nov 25 20:21:09 CST 2022, time=2022-11-25, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1089798, encodeId=0c3d1089e98bd, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/72cbdf927f7647bd84938927488b4795/94fe7f0fd8274d94807c5f3458f0c4e2.jpg, createdBy=9cd75497899, createdName=桑晒麦拉, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089797, encodeId=25af1089e97d6, content=什么是comment？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=542103, encodeId=a9be542103d1, content=从1.5分以下,现在接近2分,是好现象,这个杂志是你值得拥有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qiqi, createdTime=Fri Jul 14 18:48:00 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-14 qiqi

    从1.5分以下,现在接近2分,是好现象,这个杂志是你值得拥有

    0

共14条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分